Abstract
Tyrosine phosphorylation has a key role in intracellular signaling. Inappropriate proliferation and survival cues in tumor cells often occur as a consequence of unregulated tyrosine kinase activity. Much of the current development of anti-cancer therapies tries to target causative proteins in a specific manner to minimize side-effects. One attractive group of target proteins is the kinases. c-Kit is a receptor tyrosine kinase that normally controls the function of primitive hematopoietic cells, melanocytes and germ cells. It has become clear that uncontrolled activity of c-Kit contributes to formation of an array of human tumors. The unregulated activity of c-Kit may be due to overexpression, autocrine loops or mutational activation. This makes c-Kit an excellent target for cancer therapies in these tumors. In this review we will highlight the current knowledge on the signal transduction molecules and pathways activated by c-Kit under normal conditions and in cancer cells, and the role of aberrant c-Kit signaling in cancer progression. Recent advances in the development of specific inhibitors interfering with these signal transduction pathways will be discussed.
Keywords: Stem cell factor, c-Kit, receptor tyrosine kinase, signal transduction, transformation, cancer, leukemia
Current Cancer Drug Targets
Title: The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Volume: 6 Issue: 1
Author(s): J. Lennartsson and L. Ronnstrand
Affiliation:
Keywords: Stem cell factor, c-Kit, receptor tyrosine kinase, signal transduction, transformation, cancer, leukemia
Abstract: Tyrosine phosphorylation has a key role in intracellular signaling. Inappropriate proliferation and survival cues in tumor cells often occur as a consequence of unregulated tyrosine kinase activity. Much of the current development of anti-cancer therapies tries to target causative proteins in a specific manner to minimize side-effects. One attractive group of target proteins is the kinases. c-Kit is a receptor tyrosine kinase that normally controls the function of primitive hematopoietic cells, melanocytes and germ cells. It has become clear that uncontrolled activity of c-Kit contributes to formation of an array of human tumors. The unregulated activity of c-Kit may be due to overexpression, autocrine loops or mutational activation. This makes c-Kit an excellent target for cancer therapies in these tumors. In this review we will highlight the current knowledge on the signal transduction molecules and pathways activated by c-Kit under normal conditions and in cancer cells, and the role of aberrant c-Kit signaling in cancer progression. Recent advances in the development of specific inhibitors interfering with these signal transduction pathways will be discussed.
Export Options
About this article
Cite this article as:
Lennartsson J. and Ronnstrand L., The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer, Current Cancer Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/156800906775471725
DOI https://dx.doi.org/10.2174/156800906775471725 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Role of Oxidative Stress in Hepatitis C Virus Induced Hepatocellular Carcinoma
Current Cancer Drug Targets Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Medical Treatment of Gastrointestinal Stromal Tumors: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Synthesis and Evaluation of 2-Substituted Fendiline Analogues as Antileukemics
Letters in Drug Design & Discovery Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Targeting Histone Onco- Modifications Using Plant-Derived Products
Current Drug Targets